Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
14C-JNJ-67856633 absorption, metabolism, and excretion study in healthy men
NL-OMON50324Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of JNJ-67856633 in B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Janssen Pharmaceutical. Primary endpoints: Routes of excretion of JNJ-67856633, Metabolic pathways and predominant metabolites and 1 more. Started Aug 2021; status: completed.
02
Drugs
JNJ-67856633
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON50324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50324.